articleBiochemical JournalDec 21, 2007BRONZE OA

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

Evotec (United Kingdom) · Sepragen Corporation (United States)

PubMed
Indexed incrossrefpubmed

Abstract

The human HDAC (histone deacetylase) family, a well-validated anticancer target, plays a key role in the control of gene expression through regulation of transcription. While HDACs can be subdivided into three main classes, the class I, class II and class III HDACs (sirtuins), it is presently unclear whether inhibiting multiple HDACs using pan-HDAC inhibitors, or targeting specific isoforms that show aberrant levels in tumours, will prove more effective as an anticancer strategy in the clinic. To address the above issues, we have tested a number of clinically relevant HDACis (HDAC inhibitors) against a panel of rhHDAC (recombinant human HDAC) isoforms. Eight rhHDACs were expressed using a baculoviral system,…

No related works found for this paper.